Ownership and insider activity for PMV Pharmaceuticals, Inc. (PMVP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state.
Price
| Price | $1.43 |
| Market Cap | $76M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.3M | $73.3M | $361.4M | $172.5M | $108.3M | $37.7M | $40.9M | $38.0M |
| Short-term Investments | $31.6M | $28.2M | 0 | $124.7M | $132.8M | $165.4M | $128.6M | $75.0M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $62.2M | $102.1M | $364.8M | $301.3M | $247.0M | $207.4M | $175.7M | $115.2M |
| Property, Plant & Equipment | $1.0M | $739000 | $569000 | $13.2M | $20.5M | $19.0M | $1.6M | $1.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $63.5M | $103.0M | $365.5M | $331.6M | $270.3M | $252.2M | $191.3M | $116.6M |
| Accounts Payable | $1.0M | $2.8M | $1.6M | $3.2M | $3.0M | $3.2M | $6.6M | $3.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $352000 | 0 |
| Total Current Liabilities | $2.3M | $4.5M | $6.4M | $12.2M | $10.8M | $14.0M | $14.4M | $11.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $435000 |
| Total Liabilities | $109.6M | $173.5M | $6.4M | $23.0M | $24.3M | $26.5M | $15.2M | $11.8M |
| Retained Earnings | -$50.1M | -$75.4M | -$109.9M | -$167.7M | -$241.0M | -$310.0M | -$368.7M | -$446.5M |
| Total Equity | -$46.1M | -$70.5M | $359.1M | $308.6M | $246.0M | $225.7M | $176.1M | $104.7M |
| Total Debt | $107.2M | 0 | 0 | $11.2M | $14.0M | $13.3M | $1.2M | $838000 |
| Net Debt | $45.3M | -$101.5M | -$361.4M | -$286.0M | -$227.1M | -$189.8M | -$168.3M | -$112.1M |
| Working Capital | $59.9M | $97.6M | $358.4M | $289.1M | $236.2M | $193.4M | $161.3M | $103.8M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 7.70 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -3.41 |
Profitability
| Return on Equity | -78.11% |
| Return on Invested Capital | -111.08% |
| Return on Assets | -91.66% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACRV · ATYR · BMEA · CBUS · IMUX · LITS · RLMD
Explore sector: Healthcare · Biotechnology
More sections of PMVP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks